文献速递胸部肿瘤放疗

早期非小细胞肺癌立体定向体部放疗后症状性放射性肺炎的临床与剂量学因素

Clinical and dosimetric factors for symptomatic radiation pneumonitis after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-06-02

本研究回顾244例接受立体定向体部放疗的早期非小细胞肺癌患者,中位随访48个月,4年症状性放射性肺炎(≥2级)累积发生率为15.3%。中心型肿瘤和间质性肺炎为独立危险因素,剂量学参数中肺V10>16.7%是症状性放射性肺炎的最佳指标,建议将肺V10≤16.7%作为阈值。

要点

  • 中心型肿瘤和间质性肺炎是症状性放射性肺炎的独立危险因素。
  • 肺V8、V10、V20和平均肺剂量均与症状性放射性肺炎相关。
  • 肺V10>16.7%是症状性放射性肺炎的最佳剂量学指标,建议肺V10≤16.7%作为阈值。

核心结论

  • 中心型肿瘤和间质性肺炎是症状性放射性肺炎的独立危险因素。
  • 肺V10≤16.7%被推荐作为立体定向体部放疗的阈值。

研究设计与样本

  • 回顾性分析244例接受立体定向体部放疗的早期非小细胞肺癌患者。
  • 主要终点为≥2级放射性肺炎的发生率,采用Gray检验和Fine-Gray模型分析。

主要发现

  • 中位随访48个月,4年≥2级放射性肺炎累积发生率为15.3%。
  • 多因素分析显示中心型肿瘤和间质性肺炎仍为显著因素(p<0.001,p=0.002)。
  • 剂量参数中肺V8、V10、V20和平均肺剂量与放射性肺炎相关(p=0.012、0.011、0.022、0.014)。
  • Fine-Gray模型和ROC曲线分析显示肺V10>16.7%是症状性放射性肺炎的最佳指标。

关键数值与推荐

  • 肺V10>16.7%为症状性放射性肺炎的最佳剂量学指标,推荐肺V10≤16.7%作为阈值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The present study attempted to identify risk factors for symptomatic radiation pneumonitis (RP) after stereotactic body radiotherapy (SBRT) in patients with early-stage non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We reviewed 244 patients with early-stage NSCLC treated with SBRT. The primary endpoint was the incidence of grade ≥2 RP. Gray's test was performed to examine the relationship between clinical risk factors and grade ≥2 RP, and the Fine-Gray model was used for a multivariate analysis. The effects of each dose parameter on grade ≥2 RP were evaluated with the Fine-Gray model and optimal thresholds were tested using receiver operating characteristic (ROC) curves. RESULTS: With a median follow-up period of 48 months, the 4-year cumulative incidence of grade ≥2 RP was 15.3%. Gray's test revealed that tumor size, a central tumor, interstitial pneumonia, and the biologically effective dose correlated with RP. In the multivariate analysis, a central tumor and interstitial pneumonia remained significant factors (p < 0.001, p = 0.002). Among dose parameters, the total lung volume (%) receiving at least 8 Gy (V8), V10, V20, and the mean lung dose correlated with RP (p = 0.012, 0.011, 0.022, and 0.014, respectively). The results of the Fine-Gray model and ROC curve analyses showed that V10 >16.7% was the best indicator of symptomatic RP among dose parameters. CONCLUSION: The present results suggest that a central tumor and interstitial pneumonia are independent risk factors for symptomatic RP and lung V10 ≤16.7% is recommended as the threshold in SBRT.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kita N, Tomita N, Takaoka T, et al. Clinical and dosimetric factors for symptomatic radiation pneumonitis after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Clin Transl Radiat Oncol. 2023. PMID: 37346273. doi:10.1016/j.ctro.2023.100648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。